Therapeutic blockade of the programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) pathway has been demonstrated to bring durable antitumor response by clinical trials and transformed the treatment of a wide range of advanced cancers, including non–small cell lung cancer (NSCLC) (1). Here, CD274 is linked to cancer.